A Phase Ib/Ⅱ Clinical Trial of LBL-024 Combined With Paclitaxel in Patients With Platinum-resistant Ovarian Cancer

This study is testing a combination of an experimental drug (LBL-024, a type of immunotherapy) with paclitaxel (a standard chemotherapy) in women with platinum-resistant ovarian cancer — meaning their cancer stopped responding to platinum-based chemotherapy. The goal is to see if this combination can produce better results than chemotherapy alone. **You may be eligible if...** - You are 18 or older - You have been diagnosed with ovarian cancer that has stopped responding to platinum-based chemotherapy - Your cancer is measurable on imaging scans (based on standard RECIST criteria) - You are in reasonably good physical condition (ECOG 0–1) - Your expected survival is at least 12 weeks - Your blood counts and organ function meet the required levels **You may NOT be eligible if...** - Your cancer still responds to platinum-based chemotherapy - You have significant uncontrolled medical conditions - You have received too many prior lines of therapy - You are pregnant or breastfeeding - Your organ function does not meet the required levels Talk to your doctor to see if this trial is right for you.